Alkermes licenses Medifusion technology to develop TNF receptor-Fc fusion protein

[News]

Alkermes, Inc. and Acceleron Pharma, Inc. today announced that Alkermes has licensed a proprietary long-acting Fc fusion technology platform, called the Medifusion™ technology, which is designed to extend the circulating half-life of proteins and peptides.

More... (http://www.news-medical.net/news/20091204/Alkermes-licenses-Medifusion-technology-to-develop-TNF-receptor-Fc-fusion-protein.aspx)